An Open-label, Multicenter, Dose Escalation and Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics, and Anti-tumor Activity of GI-102, a CD80-IgG4 Fc-IL-2v Bispecific Fusion Protein, As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced or Metastatic Solid Tumors (KEYNOTE-G08)
Overview
- Phase
- Phase 1
- Intervention
- GI-102
- Conditions
- Advanced Solid Tumor
- Sponsor
- GI Innovation, Inc.
- Enrollment
- 358
- Locations
- 10
- Primary Endpoint
- Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose escalation phase of Part A and B)
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.
Detailed Description
This is a phase 1/2, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, and anti-tumor effect of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors. This study is adaptive in nature. The study is composed of four parts: * Part A: Dose escalation and optimization phase of GI-102 intravenous (IV) monotherapy * Part A dose escalation phase * Part A dose optimization phase: Dose optimization cohorts in patients with 2L+, CPI-refractory metastatic melanoma * Part B: Dose escalation and expansion phase of GI-102 subcutaneous (SC) monotherapy * Part C: Indication specific cohorts of GI-102 IV in combination with conventional anti-cancer drugs or trastuzumab deruxtecan (T-DXd) * Part D: Indication specific cohorts of GI-102 IV in combination with pembrolizumab GI-102 is a novel bi-specific Fc fusion protein containing the CD80 ectodomain as an N-terminal moiety and an interleukin (IL)-2 variant as a C-terminal moiety configurated via a human immunoglobulin G4 (IgG4) Fc. GI-102 has unique characteristics by having bispecificity to CD80 and IL2Rβγ. The CD80 portion is responsible for targeting tumor/immune cells while blocking CTLA-4 expressed on the Treg cells. The IL-2v of GI-102 is designed to abolish IL-2Rα affinity and therefore minimize the effect on Treg while it has very outstanding effect on NK and CD8 T cell proliferation and activity through IL-2Rbr affinity.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Males and females aged ≥ 18 years (or ≥ 19 years according to local regulatory guidelines) at the time of screening.
- •Has adequate organ and marrow function as defined in protocol.
- •Measurable disease as per RECIST v1.
- •ECOG performance status 0-
- •Adverse events related to any prior chemotherapy, radiotherapy, immunotherapy, other prior systemic anti-cancer therapy, or surgery must have resolved to Grade ≤1, except alopecia and Grade 2 peripheral neuropathy.
- •HIV infected patients must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease as defined in protocol.
Exclusion Criteria
- •Has known active CNS metastases and/or carcinomatous meningitis.
- •An active second malignancy.
- •Has active or a known history of Hepatitis B or known active Hepatitis C virus infection.
- •Has active tuberculosis or has a known history of active tuberculosis.
- •Active or uncontrolled infections, or severe infection within 4 weeks before study treatment administration.
- •History of chronic liver disease or evidence of hepatic cirrhosis, except patients with liver metastasis.
- •Has an active autoimmune disease that has required systemic treatment in past 2 years.
- •Previous immunotherapies related to mode of action of GI-
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive medications within 2 weeks prior to Cycle 1 Day
- •Administration of prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment.
Arms & Interventions
GI-102 + eribulin
Intervention: GI-102
GI-102
Dose escalation: GI-102 intravenous (IV), multiple ascending doses Dose optimization: GI-102 intravenous (IV), sRP2D Dose optimization: GI-102 intravenous (IV), sRP2D-1 (or sRP2D+1)
Intervention: GI-102
GI-102 subcutaneous (SC)
Dose escalation: GI-102 subcutaneous (SC), multiple ascending doses Dose expansion: GI-102 subcutaneous (SC), sRP2D
Intervention: GI-102 subcutaneous (SC)
GI-102 + doxorubicin
Intervention: doxorubicin
GI-102 + doxorubicin
Intervention: GI-102
GI-102 + paclitaxel + bevacizumab
Intervention: paclitaxel
GI-102 + paclitaxel + bevacizumab
Intervention: bevacizumab
GI-102 + paclitaxel + bevacizumab
Intervention: GI-102
GI-102 + eribulin
Intervention: eribulin
GI-102 + trastuzumab deruxtecan (T-DXd)
Intervention: trastuzumab deruxtecan (T-DXd)
GI-102 + trastuzumab deruxtecan (T-DXd)
Intervention: GI-102
GI-102 + pembrolizumab
Intervention: pembrolizumab
GI-102 + pembrolizumab
Intervention: GI-102
Outcomes
Primary Outcomes
Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose escalation phase of Part A and B)
Time Frame: Study Day 1, assessed up to DLT period (3 weeks after treatment)
A DLT is defined as a clinically significant AE (classified according to the NCI CTCAE version 5) or significant laboratory abnormality that occur during the DLT assessment periods, during dose escalation and dose expansion, and is considered by the Investigator to be related to GI-102.
Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs) (dose escalation phase of Part A and B)
Time Frame: Study Day 1, assessed up to approximately 24 months
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. All AE events will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
Objective Response Rate (ORR) (dose optimization phase of Part A, dose expansion phase of Part B, Part C and D)
Time Frame: Study Day 1, assessed up to approximately 24 months
ORR is defined as the percentage of participants with investigator-assessed objective response of complete response (CR) or partial response (PR). PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker levels (as applicable to non-target lesions).
Secondary Outcomes
- Objective Response Rate (ORR) (dose escalation phase of Part A and B)(Study Day 1, assessed up to approximately 24 months)
- Incidence and nature of Dose-Limiting Toxicity (DLTs) (dose optimization phase of Part A, dose expansion phase of Part B, Part C and D)(Study Day 1, assessed up to DLT period (3 weeks after treatment))
- Incidence, nature, and severity of adverse events (AEs) and immune-related AEs (irAEs) (dose optimization phase of Part A, dose expansion phase of Part B, Part C and D)(Study Day 1, assessed up to approximately 24 months)
- Disease Control Rate (DCR)(Study Day 1, assessed up to approximately 24 months)
- Duration of objective response (DoR)(Study Day 1, assessed up to approximately 24 months)
- Progression-free survival (PFS)(6-month, 12-month, and 18-month)
- Overall survival (OS)(12-month and 18-month)
- Peak plasma concentration (Cmax) of GI-102(Study Day 1, assessed up to approximately 24 months)
- Half-life of GI-102 (T1/2)(Study Day 1, assessed up to approximately 24 months)
- Area under the plasma concentration versus time curve (AUC) of GI-102(Study Day 1, assessed up to approximately 24 months)
- Clearance of GI-102(Study Day 1, assessed up to approximately 24 months)
- Volume of distribution (Vd) of GI-102 after administration(Study Day 1, assessed up to approximately 24 months)